These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33575471)

  • 61. CircTP63 promotes cell proliferation and invasion by regulating EZH2 via sponging miR-217 in gallbladder cancer.
    Wang S; Tong H; Su T; Zhou D; Shi W; Tang Z; Quan Z
    Cancer Cell Int; 2021 Nov; 21(1):608. PubMed ID: 34789260
    [TBL] [Abstract][Full Text] [Related]  

  • 62. SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway.
    Shu YJ; Weng H; Ye YY; Hu YP; Bao RF; Cao Y; Wang XA; Zhang F; Xiang SS; Li HF; Wu XS; Li ML; Jiang L; Lu W; Han BS; Jie ZG; Liu YB
    Mol Cancer; 2015 Jan; 14(1):12. PubMed ID: 25623055
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MicroRNA-29c-5p suppresses gallbladder carcinoma progression by directly targeting CPEB4 and inhibiting the MAPK pathway.
    Shu YJ; Bao RF; Jiang L; Wang Z; Wang XA; Zhang F; Liang HB; Li HF; Ye YY; Xiang SS; Weng H; Wu XS; Li ML; Hu YP; Lu W; Zhang YJ; Zhu J; Dong P; Liu YB
    Cell Death Differ; 2017 Mar; 24(3):445-457. PubMed ID: 28060377
    [TBL] [Abstract][Full Text] [Related]  

  • 64. MicroRNA aberrations: An emerging field for gallbladder cancer management.
    Chandra V; Kim JJ; Mittal B; Rai R
    World J Gastroenterol; 2016 Feb; 22(5):1787-99. PubMed ID: 26855538
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer.
    García P; Rosa L; Vargas S; Weber H; Espinoza JA; Suárez F; Romero-Calvo I; Elgueta N; Rivera V; Nervi B; Obreque J; Leal P; Viñuela E; Aguayo G; Muñiz S; Sagredo A; Roa JC; Bizama C
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218280
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer.
    Wang YF; Feng FL; Zhao XH; Ye ZX; Zeng HP; Li Z; Jiang XQ; Peng ZH
    World J Gastroenterol; 2014 Apr; 20(14):4085-92. PubMed ID: 24744600
    [TBL] [Abstract][Full Text] [Related]  

  • 67. miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1.
    Zhan M; Zhao X; Wang H; Chen W; Xu S; Wang W; Shen H; Huang S; Wang J
    Tumour Biol; 2016 Aug; 37(8):10553-62. PubMed ID: 26852750
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prognostic value of TROP2 expression in patients with gallbladder cancer.
    Chen MB; Wu HF; Zhan Y; Fu XL; Wang AK; Wang LS; Lei HM
    Tumour Biol; 2014 Nov; 35(11):11565-9. PubMed ID: 25135430
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Establishment and characterization of 38 novel patient-derived primary cancer cell lines using multi-region sampling revealing intra-tumor heterogeneity of gallbladder carcinoma.
    Feng F; Cheng Q; Li B; Liu C; Wang H; Li B; Xu X; Yu Y; Chen Z; Wu X; Dong H; Chu K; Xie Z; Gao Q; Xiong L; Li F; Yi B; Zhang D; Jiang X
    Hum Cell; 2021 May; 34(3):918-931. PubMed ID: 33813726
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lysine-specific demethylase 1 promotes tumorigenesis and predicts prognosis in gallbladder cancer.
    Lian SX; Shao YB; Liu HB; He JY; Lu WQ; Zhang Y; Jiang Y; Zhu J
    Oncotarget; 2015 Oct; 6(32):33065-76. PubMed ID: 26460616
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Decreased expression of hsa‑miR‑372 predicts poor prognosis in patients with gallbladder cancer by affecting chloride intracellular channel 1.
    Zhou N; Cheng W; Peng C; Liu Y; Jiang B
    Mol Med Rep; 2017 Nov; 16(5):7848-7854. PubMed ID: 28944858
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Annexin A4-nuclear factor-κB feedback circuit regulates cell malignant behavior and tumor growth in gallbladder cancer.
    Yao HS; Sun C; Li XX; Wang Y; Jin KZ; Zhang XP; Hu ZQ
    Sci Rep; 2016 Aug; 6():31056. PubMed ID: 27491820
    [TBL] [Abstract][Full Text] [Related]  

  • 73. UHRF1 depletion suppresses growth of gallbladder cancer cells through induction of apoptosis and cell cycle arrest.
    Qin Y; Wang J; Gong W; Zhang M; Tang Z; Zhang J; Quan Z
    Oncol Rep; 2014 Jun; 31(6):2635-43. PubMed ID: 24756644
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer.
    Jiang TY; Feng XF; Fang Z; Cui XW; Lin YK; Pan YF; Yang C; Ding ZW; Zhang YJ; Tan YX; Wang HY; Dong LW
    Cancer Lett; 2021 Mar; 501():187-199. PubMed ID: 33220333
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Proteomic analysis identifies dysregulated proteins and associated molecular pathways in a cohort of gallbladder cancer patients of African ancestry.
    Baichan P; Naicker P; Augustine TN; Smith M; Candy G; Devar J; Nweke EE
    Clin Proteomics; 2023 Mar; 20(1):8. PubMed ID: 36855072
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gallbladder cancer: Progress in the Indian subcontinent.
    Kumar A; Sarangi Y; Gupta A; Sharma A
    World J Clin Oncol; 2024 Jun; 15(6):695-716. PubMed ID: 38946839
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Epigenetic changes in carcinogenesis of gallbladder.
    Tewari M; Agarwal A; Mishra RR; Meena RN; Shukla HS
    Indian J Surg Oncol; 2013 Dec; 4(4):356-61. PubMed ID: 24426757
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer.
    Barton KN; Siddiqui F; Pompa R; Freytag SO; Khan G; Dobrosotskaya I; Ajlouni M; Zhang Y; Cheng J; Movsas B; Kwon D
    Mol Ther Oncolytics; 2021 Mar; 20():94-104. PubMed ID: 33575474
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
    Quinonero F; Cepero A; Urbano D; Munoz-Gamez JA; Martin-Guerrero SM; Martin-Oliva D; Prados J; Melguizo C; Ortiz R
    J Biosci; 2021; 46():. PubMed ID: 33576344
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
    Shah MA; Bodoky G; Starodub A; Cunningham D; Yip D; Wainberg ZA; Bendell J; Thai D; He J; Bhargava P; Ajani JA
    J Clin Oncol; 2021 Mar; 39(9):990-1000. PubMed ID: 33577358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.